In the present study, we successfully downscaled, for the first time, the in situ intestinal perfusion technique with mesenteric blood sampling from rat to mouse. In order to evaluate the feasibility of this approach, we assessed the apparent permeability (P app ) of mouse intestine for a set of marker compounds (atenolol: paracellular transport, metoprolol: transcellular transport, talinolol: Pglycoprotein (P-gp) mediated efflux) in both wild-type and P-gp deficient mice. In wild-type mice, the observed P app -values for atenolol (1.8±0.3⋅10
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INTRODUCTION
Accurate assessment of intestinal permeability for drugs and drug candidates intended for oral administration is crucial to making rational decisions according to the absorption potential and to unraveling absorption mechanisms that may explain limited and/or variable bioavailability. For instance, intestinal metabolism and active transport (uptake or efflux) might affect the rate of transepithelial drug transport and mediate drug-drug and drug-food interactions, possibly causing variable drug disposition, decreased efficiency or unwanted side effects (Fleisher et al., 1999; Custodio et al., 2008) . Among the variety of permeability models available to study transepithelial transport, the in situ intestinal perfusion technique with mesenteric blood sampling in animal models (mostly rats) is the appropriate approach when biorelevance and accurate prediction rather than high-throughput are required. The technique provides the best simulation of the in vivo situation (e.g. relevant barrier functions and sink conditions). In particular, the biorelevant expression of intestinal enzymes and transporters makes the model well suited to elucidate their impact on the absorption process, even though interspecies differences may complicate extrapolation to humans.
Obviously, the ability to inhibit specific enzymes or carriers is of great assistance in mechanistic transport studies. While various inhibitors of enzymes and carriers are available, their sometimes limited potency and poor specificity may complicate data interpretation (Xia et al., 2007) . Therefore, permeability assessment in mutant or knockout animals lacking expression of genes that encode specific enzymes or transporters modulating drug absorption, is an extremely valuable tool to discern the exact role of these individual transporters or enzymes. For instance, intestinal perfusion in rats carrying a Mrp2-deficient gene has been conducted to investigate the role of this efflux transporter in the intestinal disposition of quercetin (Sesink et al., 2005) . Unfortunately, the availability of relevant mutant rats is limited and the technology to create knockout rats is still in its infancy (van Boxtel et al., 2008) . In contrast, knockout mice are readily available (Xia et al., 2007) but performing the surgical techniques required for in situ intestinal perfusion with mesenteric blood sampling on animals as small as mice turned out to be very challenging. Only a few papers report on the application of in situ intestinal perfusion in mice (Adachi et al., 2003 (Adachi et al., , 2005 Hu et al., 2008) . However, only drug disappearance from This article has not been copyedited and formatted. The final version may differ from this version. 5 the perfusate (effective permeability) was monitored in these studies; no mesenteric blood was collected. This approach has some serious drawbacks and limitations (Brouwers et al., 2009) . First, the assumption that drug disappearance reflects drug uptake in the enterocytes is not valid when the compound is unstable or suffers from non-specific binding to the tubing or the gut wall. Moreover, assessment of the effective permeability coefficient only provides valuable information on drug transport into the blood circulation when uptake into the enterocytes is rate-limiting to the overall absorption (Lennernäs, 2007) . Although likely in the case of passively absorbed, stable compounds, this assumption fails when the compound is metabolized by or accumulates in enterocytes or when carriers affect transport to the portal blood (Bohets et al., 2001) . It is obvious that the full exploitation of the intestinal perfusion technique in mice requires the implementation of mesenteric blood sampling and calculation of apparent permeability coefficients. To our knowledge, this has not yet been reported in the literature.
The purpose of the present study was to downscale the in situ intestinal perfusion technique with mesenteric blood sampling to mice. In order to explore the feasibility of this approach and to illustrate its potential importance, we evaluated the permeability of mouse intestinal tissue for a set of marker compounds in both wild-type and mdr1a/1b (-/-) knockout mice.
METHODS
Chemicals.
The following chemicals were used in the study: atenolol, metoprolol tartrate, propranolol and verapamil hydrochloride (Sigma-Aldrich, St. Louis, MO), talinolol (kindly provided by Arzneimittelwerk Dresden, Radebeul, Germany), ketamin (Anesketin; Eurovet, Heusden, Belgium), xylazin (Xyl-M 2%; VMD, Arendonk, Belgium), sodium acetate trihydrate (Acros Organics, Geel, Belgium), acetonitrile, methanol and dichloromethane (Fisher Scientific, Leicestershire, UK), Hanks' Balanced Salt Solution (HBSS) and HEPES (Invitrogen, Merelbeke, Belgium). Water was purified with a Maxima system (Elga Ltd., High Wycombe Bucks, UK).
In situ intestinal perfusion in mice. The setup for the in situ perfusion experiments in mice was based on a previously described method in rats (Mellaerts et al., 2008) . Experiments were performed in This article has not been copyedited and formatted. The final version may differ from this version. The perfusion experiments were performed using a closed-loop set-up with recirculation of the perfusate (perfusate volume 5 ml). The perfusate consisted of transport medium containing a mixture of the marker compounds atenolol (100 µM), talinolol (100 µM) and metoprolol (20 µM) in absence or presence of the P-gp inhibitor verapamil (150 µM). The perfusion rate amounted to 0.2 ml.min -1 .
During the perfusion, blood was collected from the mesenteric vein and heparinized donor blood
[supplemented with ketamin-xylazin (22.0 and 1.83 mg.kg -1 .h -1 , respectively)] was supplied via the jugular vein at a rate of 50 µl.min -1 using a syringe pump (Pilot A2, Fresenius Vial, Grenoble, France).
Blood samples were collected from the mesenteric vein for 60 min over 5-min time intervals. In This article has not been copyedited and formatted. The final version may differ from this version. Analysis of marker compounds. Prior to quantification by HPLC, atenolol, talinolol and metoprolol were extracted from the blood samples. An amount of 150 µl blood was diluted in 1250 µl of HCl 0.2 M and 100 µl internal standard solution (propranolol 2 µM in transport medium). After alkalinization with 500 µl NaOH 2 M, the mixture of marker compounds was extracted with 10 ml of dichloromethane. Upon centrifugation (4000 rpm, 10 min), removal of the water layer and evaporation of the organic solvent, the residue was dissolved in 150 µl of transport medium for HPLC analysis. For concentration determination, a calibration curve using spiked blood samples was prepared and treated in the same way as the samples. The concentrations of atenolol, talinolol and metoprolol in perfusate and extracted blood samples were determined by a HPLC assay described by Augustijns and Mols (2004) .
Calculations and data analysis. For each compound, the apparent permeability coefficient (P app )
was calculated according to Equation 1:
with Q the cumulative amount of drug appearing in the mesenteric blood as a function of time t in steady state conditions (see Fig. 1 ), A the surface area of the perfused cylindrical segment and C donor the drug concentration in the perfusate. C donor did not significantly decrease during the experiments, as confirmed by analysis of the collected perfusate samples (data not shown). P app -values among the different transport conditions were compared using one-way analysis of variance and Tukey's multiple comparison test. Differences were considered statistically significant at p< 0.05.
RESULTS AND DISCUSSION
In this study, we explored the feasibility of downscaling the in situ intestinal perfusion model with mesenteric blood sampling to mice. We evaluated the apparent permeability of perfused mouse intestine This article has not been copyedited and formatted. The final version may differ from this version. (Hayeshi et al., 2008) . The mixture includes markers for passive paracellular (atenolol) and transcellular (metoprolol) transport and a marker for P-gp mediated efflux (talinolol).
Downscaling the intestinal perfusion technique to mice.
Based on the in-house experience with the in situ perfusion approach in rats (Annaert et al., 2000; Deferme et al., 2002; van Gelder et al., 2002; Mols et al., 2005; Mellaerts et al., 2008) , we successfully downscaled the technique to mice. The mean mesenteric blood flow rate (calculated based on the collected blood volumes) amounted to 46±13
µl.min -1 , which corresponds to the infusion rate of donor blood (50 µl.min Obviously, the determination of reliable apparent permeability coefficients according to Equation 1 requires steady state.
Permeability assessment in NMRI mice in absence and presence of a P-gp inhibitor. In a first set of experiments, the intestinal permeability for the marker compounds was assessed in male NMRI mice in absence or presence of the P-gp inhibitor verapamil (Fig. 2) . As observed in other models for permeability assessment (Brouwers et al., 2009) , the apparent permeability for atenolol (paracellular route) was significantly lower than the permeability for metoprolol (transcellular route); this reflects the This article has not been copyedited and formatted. The final version may differ from this version. limited contribution of the paracellular pathway to transepithelial transport. While the presence of verapamil did not significantly affect the permeability for atenolol and metoprolol, a 5-fold increase in the permeability for the P-gp substrate talinolol was observed (p < 0.05). It is important to note that the P app -values observed in NMRI mice were similar to P app -values previously determined in Wistar rats with the same perfusion technique (Fig. 3) . This suggests comparable passive barrier functions (paraand transcellular) and P-gp-mediated efflux in mice and rats.
Permeability assessment in wild-type and mdr1a/1b (-/-) FVB mice. As discussed in the introduction, one of the most important advantages of using mice in the in situ perfusion model is the availability of knockout mice lacking expression of a specific transporter or enzyme modulating drug absorption. In the present study, we used mdr1a/1b (-/-) FVB mice with a normal viability, but inactivated mdr1a and mdr1b genes, both encoding the efflux carrier P-gp (Schinkel et al., 1997 ). An increased oral bioavailability of various P-gp substrates in mdr1a/1b (-/-) mice versus wild-type mice has previously been demonstrated (Bardelmeijer et al., 2000 (Bardelmeijer et al., , 2002 Lagas et al., 2008) .
In Fig. 4 , the apparent permeability for the marker compounds atenolol, metoprolol and talinolol is compared between wild-type and mdr1a/1b (-/-) FVB mice. P app -values in wild-type FVB mice did not significantly differ from P app -values in the NMRI mice (Fig. 2) . As expected, no significant differences in apparent permeability for the passively transported atenolol and metoprolol were observed between wild-type and knockout mice. In contrast, the permeability for the P-gp substrate talinolol was 6.9-fold higher in mdr1a/1b (-/-) mice versus wild-type mice (p < 0.01).
The addition of verapamil to the perfusate did not further increase talinolol uptake in mdr1a/1b (-/-) mice; in contrast, the P app -value slightly decreased, although not statistically significant (8.3 ± 1.9 versus 5.4 ± 1.8 ·
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-6 cm/s in absence or presence of verapamil, respectively). A similar decreasing effect of verapamil (not statistically significant) on the P app -values of metoprolol, was observed in both NMRI (Fig. 2) , wild-type FVB (49.1 ± 10.9 versus 40.6 ± 18.4 This article has not been copyedited and formatted. The final version may differ from this version. 
